Inactivation of Middle East respiratory syndrome coronavirus (MERS‐CoV) in plasma products using a riboflavin‐based and ultraviolet light‐based photochemical treatment
Identifieur interne : 000045 ( Istex/Checkpoint ); précédent : 000044; suivant : 000046Inactivation of Middle East respiratory syndrome coronavirus (MERS‐CoV) in plasma products using a riboflavin‐based and ultraviolet light‐based photochemical treatment
Auteurs : Shawn D. Keil ; Richard Bowen ; Susanne MarschnerSource :
- Transfusion [ 0041-1132 ] ; 2016-12.
Abstract
BACKGROUND: Middle East respiratory syndrome coronavirus (MERS‐CoV) has been identified as a potential threat to the safety of blood products. The Mirasol Pathogen Reduction Technology System uses riboflavin and ultraviolet (UV) light to render blood‐borne pathogens noninfectious while maintaining blood product quality. Here, we report on the efficacy of riboflavin and UV light against MERS‐CoV when tested in human plasma. STUDY DESIGN AND METHODS: MERS‐CoV (EMC strain) was used to inoculate plasma units that then underwent treatment with riboflavin and UV light. The infectious titers of MERS‐CoV in the samples before and after treatment were determined by plaque assay on Vero cells. The treatments were initially performed in triplicate using pooled plasma (n = 3) and then repeated using individual plasma units (n = 6). RESULTS: In both studies, riboflavin and UV light reduced the infectious titer of MERS‐CoV below the limit of detection. The mean log reductions in the viral titers were ≥4.07 and ≥4.42 for the pooled and individual donor plasma, respectively. CONCLUSION: Riboflavin and UV light effectively reduced the titer of MERS‐CoV in human plasma products to below the limit of detection, suggesting that the treatment process may reduce the risk of transfusion transmission of MERS‐CoV.
Url:
DOI: 10.1111/trf.13860
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:D967E796D9878ECB9CA79E08A332E61DEFAF9E53Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inactivation of Middle East respiratory syndrome coronavirus (MERS‐CoV) in plasma products using a riboflavin‐based and ultraviolet light‐based photochemical treatment</title><author><name sortKey="Keil, Shawn D" sort="Keil, Shawn D" uniqKey="Keil S" first="Shawn D." last="Keil">Shawn D. Keil</name></author><author><name sortKey="Bowen, Richard" sort="Bowen, Richard" uniqKey="Bowen R" first="Richard" last="Bowen">Richard Bowen</name></author><author><name sortKey="Marschner, Susanne" sort="Marschner, Susanne" uniqKey="Marschner S" first="Susanne" last="Marschner">Susanne Marschner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D967E796D9878ECB9CA79E08A332E61DEFAF9E53</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/trf.13860</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-N103BXRB-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000023</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000023</idno><idno type="wicri:Area/Istex/Curation">000023</idno><idno type="wicri:Area/Istex/Checkpoint">000045</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000045</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Inactivation of Middle East respiratory syndrome coronavirus (MERS‐CoV) in plasma products using a riboflavin‐based and ultraviolet light‐based photochemical treatment</title><author><name sortKey="Keil, Shawn D" sort="Keil, Shawn D" uniqKey="Keil S" first="Shawn D." last="Keil">Shawn D. Keil</name><affiliation></affiliation><affiliation></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: shawn.keil@terumobct.com</wicri:noCountry></affiliation></author><author><name sortKey="Bowen, Richard" sort="Bowen, Richard" uniqKey="Bowen R" first="Richard" last="Bowen">Richard Bowen</name><affiliation><wicri:noCountry code="subField">Collins</wicri:noCountry></affiliation></author><author><name sortKey="Marschner, Susanne" sort="Marschner, Susanne" uniqKey="Marschner S" first="Susanne" last="Marschner">Susanne Marschner</name><affiliation><wicri:noCountry code="subField">Lakewood</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="ISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><imprint><biblScope unit="vol">56</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2948">2948</biblScope><biblScope unit="page" to="2952">2952</biblScope><biblScope unit="page-count">5</biblScope><date type="published" when="2016-12">2016-12</date></imprint><idno type="ISSN">0041-1132</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0041-1132</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">BACKGROUND: Middle East respiratory syndrome coronavirus (MERS‐CoV) has been identified as a potential threat to the safety of blood products. The Mirasol Pathogen Reduction Technology System uses riboflavin and ultraviolet (UV) light to render blood‐borne pathogens noninfectious while maintaining blood product quality. Here, we report on the efficacy of riboflavin and UV light against MERS‐CoV when tested in human plasma. STUDY DESIGN AND METHODS: MERS‐CoV (EMC strain) was used to inoculate plasma units that then underwent treatment with riboflavin and UV light. The infectious titers of MERS‐CoV in the samples before and after treatment were determined by plaque assay on Vero cells. The treatments were initially performed in triplicate using pooled plasma (n = 3) and then repeated using individual plasma units (n = 6). RESULTS: In both studies, riboflavin and UV light reduced the infectious titer of MERS‐CoV below the limit of detection. The mean log reductions in the viral titers were ≥4.07 and ≥4.42 for the pooled and individual donor plasma, respectively. CONCLUSION: Riboflavin and UV light effectively reduced the titer of MERS‐CoV in human plasma products to below the limit of detection, suggesting that the treatment process may reduce the risk of transfusion transmission of MERS‐CoV.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Bowen, Richard" sort="Bowen, Richard" uniqKey="Bowen R" first="Richard" last="Bowen">Richard Bowen</name><name sortKey="Keil, Shawn D" sort="Keil, Shawn D" uniqKey="Keil S" first="Shawn D." last="Keil">Shawn D. Keil</name><name sortKey="Marschner, Susanne" sort="Marschner, Susanne" uniqKey="Marschner S" first="Susanne" last="Marschner">Susanne Marschner</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000045 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 000045 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:D967E796D9878ECB9CA79E08A332E61DEFAF9E53
|texte= Inactivation of Middle East respiratory syndrome coronavirus (MERS‐CoV) in plasma products using a riboflavin‐based and ultraviolet light‐based photochemical treatment
}}
| This area was generated with Dilib version V0.6.33. |  |